Feb, 2018
(BUSINESS WIRE)--MabSpace Biosciences announces on February 16th, 2018 FDA cleared Investigational New Drug (IND) for MSB2311, a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with locally advanced/metastatic solid tumors.
Jan, 2018
To benefit global patients by accelerating the design and manufacturing of innovative biologics that meet global standards.
HJB, an organization dedicated to expanding global access to important protein therapeutics, today held the grand opening ceremony for its R&D Center and Manufacturing Facility.
Oct, 2017
(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd., today announced it has filed an IND application to CFDA on September 12th, 2017 for MSB2311, a second-generation PD-L1 antibody with pH-dependent antigen binding property.
Mar, 2017
HJB and G-CON Manufacturing today announced that the companies are working together on HJB’s state of the art biologics facility in the Hangzhou Economic & Technology Development Area (HEDA) in China.
Feb, 2017
(BUSINESS WIRE)--Suzhou-based MabSpace Biosciences announced that the preclinical data for its lead program MSB2311, a 2nd generation humanized PD-L1 blocking antibody with a unique pH-dependent antigen binding property, will be presented at the upcoming 2017 Inaugural American Society of Clinical Oncology (ASCO)-Society for Immunotherapy of Cancer (SITC) Annual Meeting on February 23rd-25th, 2017 in Orlando, Florida, US.
Jan, 2017
(BUSINESS WIRE)--San Diego based Ambrx Inc. and Suzhou based MabSpace Biosciences have agreed to collaborate on discovery and development of multiple novel ADCs in China and around the world for oncology.